Endocrine Abstracts

Introduction: Sodium glucose cotransporter 2 inhibitors (SGT2-i) and glucagon-like peptide-1 receptor agonists (GLP-1-ra) conform two families of drugs with beneficial effects on weight and glycemia. Our aim is to identify epidemiological and clinical characteristics of patients, candidates to receive one of these classes of drugs, that can influence on physician’s decisions.

Methods/design: Retrospective observational research. Data from patients with type 2 diabetes mellitus (T2DM) attended in a Cardiovascular Risk Factors Unit between January 2016 and December 2017, whom a SGT2-i or a GLP-1-ra was prescribed, were collected. Patients who were already taking one drug of the other class, were excluded from analysis. Univariate and multivariate analysis were performed to identify potential predictors associated with the prescription of each type of drug.

Results: Data from 150 patients were analyzed (SGT2-i and GLP-1-ra was prescribed for each 50% of the sample). Patients who received GLP1-ra for intensification, were more likely to be women (74.7% vs 30.7%, P<0.001) and younger (mean age: 55.6±10.9 vs 59.4±10.9 years, P=0.021). Also, higher body mass index (BMI) was observed among those who received GLP-1-ra (40.1±7.8 vs 33.7±6 Kg/m², P<0.001). SGT2-i was the preferred choice among patients with any documented macrovascular complication (63.4% vs 36.6%, P=0.04). In multivariant analysis, age (younger) (OR: 6.8 [95% IC: 3.1–15.4], P< 0.001), higher BMI (OR: 3 [95% CI: 1.4–15.4], P=0.006), and gender (female) (OR: 1.04 [95% CI: 1–1.1], P=0.039), were associated with GLP-1-ra prescription.

Conclusions: Female gender, younger age and higher BMI are clinical determinants that influence clinical decisions to prescibe antidiabetic drugs with beneficial effects on weight.